No Data
LENZ Therapeutics Analyst Ratings
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38
Leerink Partners Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $36
LENZ Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Lenz Therapeutics Inc - Qtrly Shr Loss $0.38
LENZ Therapeutics Q3 2024 GAAP EPS $(0.38) Beats $(0.47) Estimate, Cash, Cash Equivalents And Marketable Securities Of $217.2M With Cash Runway Anticipated To Extend To Post-Launch Positive Operating Cash Flow
No Data
No Data